With the rapid development of the biopharmaceutical industry, there is an increasing demand for drug development and efficacy evaluation. Against this backdrop, InnoModels Biotechnology has revolutionized the drug discovery and development field with its CDX in vivo efficacy testing platform. The platform not only has more than 500 validated tumor cell lines, but also can perform a variety of in vivo efficacy and PK/PD experiments including subcutaneous, in situ and systemic inoculation.
Highly Diverse Tumor Cell Lines
The CDX in vivo efficacy testing platform of InnoModels Biotechnology has over 500 validated tumor cell lines, covering a wide range of cancer types. This means that researchers can select the most appropriate tumor cell lines for drug screening and efficacy assessment according to different research needs. This highly diverse range of tumor cell lines provides a more comprehensive and precise experimental basis for drug development.
comprehensive coverage of in vivo drug efficacy experiments
In addition to a rich variety of tumor cell lines, the CDX platform of InnoModels Biotechnology is also capable of conducting various in vivo efficacy experiments, including subcutaneous, in situ inoculation, and systemic inoculation. These experimental methods can simulate the real action environment of drugs in vivo, so as to more accurately assess the efficacy and safety of drugs. In addition, the platform can be used in combination with PBMC humanized immune system reconstructed mice and CD34+HSC humanized immune system humanized mice, further improving the reliability and accuracy of the experiments.

Highly efficient PK/PD experimental capability
In addition to in vivo efficacy experiments, InnoModels' CDX platform is also equipped with powerful PK/PD (pharmacokinetic/pharmacodynamic) experimental capabilities. By conducting detailed studies on the absorption, distribution, metabolism and excretion of drugs in the body, we can gain a deeper understanding of the drug's mechanism of action and efficacy characteristics. This provides strong support for optimization and improvement in the drug development process.
Innovative Technical Support
InnoModels' CDX platform also relies on its self-developed NIG mice and other advanced technologies. These technologies have higher levels of innate immunity and are more tolerant to specific types of tumor cells such as BAF3 engineered cell lines. This means that when conducting in vivo drug efficacy experiments, they can better mimic the real human environment, thus improving the accuracy and reliability of the experiments.
In conclusion, with its highly diversified tumor cell lines, comprehensive coverage of in vivo efficacy experiments, highly efficient PK/PD experimental capabilities, and innovative technological support, InnoModels' CDX modeling platform has brought about a revolutionary change in the field of drug discovery and efficacy evaluation. The application of this platform is expected to promote the acceleration of the drug development process and the rapid launch of new drugs, and make greater contributions to the cause of human health.